Follow
Paraskevi Giannakakou
Paraskevi Giannakakou
Professor of pharmacology in Medicine, Weill Cornell
Verified email at med.cornell.edu
Title
Cited by
Cited by
Year
Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation
H Zhang, D Freitas, HS Kim, K Fabijanic, Z Li, H Chen, MT Mark, H Molina, ...
Nature cell biology 20 (3), 332-343, 2018
13232018
Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization
P Giannakakou, DL Sackett, YK Kang, Z Zhan, JTM Buters, T Fojo, ...
Journal of Biological Chemistry 272 (27), 17118-17125, 1997
9171997
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
NJ Mabjeesh, D Escuin, TM LaVallee, VS Pribluda, GM Swartz, ...
Cancer cell 3 (4), 363-375, 2003
9132003
Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®)
RJ Kowalski, P Giannakakou, E Hamel
Journal of Biological Chemistry 272 (4), 2534-2541, 1997
7181997
Synthesis of epothilones A and B in solid and solution phase
KC Nicolaou, N Winssinger, J Pastor, S Ninkovic, F Sarabia, Y He, ...
Nature 387 (6630), 268-272, 1997
6311997
A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells
P Giannakakou, R Gussio, E Nogales, KH Downing, D Zaharevitz, ...
Proceedings of the National Academy of Sciences 97 (6), 2904-2909, 2000
6262000
Targeting microtubules for cancer chemotherapy
J Zhou, P Giannakakou
Current Medicinal Chemistry-Anti-Cancer Agents 5 (1), 65-71, 2005
6162005
Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death
MV Blagosklonny, P Giannakakou, WS El-Deiry, DGI Kingston, PI Higgs, ...
Cancer research 57 (1), 130-135, 1997
5221997
Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways
TH Wang, HS Wang, H Ichijo, P Giannakakou, JS Foster, T Fojo, ...
Journal of Biological Chemistry 273 (9), 4928-4936, 1998
5061998
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer
MS Darshan, MS Loftus, M Thadani-Mulero, BP Levy, D Escuin, XK Zhou, ...
Cancer research 71 (18), 6019-6029, 2011
4792011
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody
JP Gleghorn, ED Pratt, D Denning, H Liu, NH Bander, ST Tagawa, ...
Lab on a Chip 10 (1), 27-29, 2010
4642010
p53 is associated with cellular microtubules and is transported to the nucleus by dynein
P Giannakakou, DL Sackett, Y Ward, KR Webster, MV Blagosklonny, ...
Nature cell biology 2 (10), 709-717, 2000
4622000
The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more …
RJ Kowalski, P Giannakakou, SP Gunasekera, RE Longley, BW Day, ...
Molecular pharmacology 52 (4), 613-622, 1997
3431997
The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for …
DE Pryor, A O'Brate, G Bilcer, JF Díaz, Y Wang, Y Wang, M Kabaki, ...
Biochemistry 41 (29), 9109-9115, 2002
3122002
Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity
P Giannakakou, R Robey, T Fojo, MV Blagosklonny
Oncogene 20 (29), 3806-3813, 2001
3032001
Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study
AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ...
Journal of Clinical Oncology 37 (13), 1120, 2019
3012019
The importance of p53 location: nuclear or cytoplasmic zip code?
A O’Brate, P Giannakakou
Drug resistance updates 6 (6), 313-322, 2003
2962003
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device
BJ Kirby, M Jodari, MS Loftus, G Gakhar, ED Pratt, C Chanel-Vos, ...
PloS one 7 (4), e35976, 2012
2912012
Androgen receptor splice variants determine taxane sensitivity in prostate cancer
M Thadani-Mulero, L Portella, S Sun, M Sung, A Matov, RL Vessella, ...
Cancer research 74 (8), 2270-2282, 2014
2662014
A SIRT2-selective inhibitor promotes c-Myc oncoprotein degradation and exhibits broad anticancer activity
H Jing, J Hu, B He, YLN Abril, J Stupinski, K Weiser, M Carbonaro, ...
Cancer cell 29 (3), 297-310, 2016
2592016
The system can't perform the operation now. Try again later.
Articles 1–20